CorDx’s Post

I can’t wait to connect and collaborate at BIO 2024. Especially eager to discuss pain points in clinical development pipelines. You can contact me by email. Or request a meeting via the BIO partnering system: https://lnkd.in/gzSnamDw Want to hear how autoantibodies can enable precision medicine? Oncimmune’s CEO Martin Gouldstone and other panel members will be discussing just that: https://lnkd.in/gtN_cV_7 #BIO2024 #Oncimmune #autoantibodies #precisionmedicine

Between new data coming out of conferences, new insights into adalimumab biosimilars, and a study evaluating the impact of biosimilars on patient out-of-pocket costs, the biosimilar space had a very eventful March. https://lnkd.in/gvWPxFn3

This week, I was thrilled to see the latest insights from the cutting-edge field of Live Biotherapeutic Products (LBPs)!  According to the latest study by InsightAce, the LBP market is on an incredible growth trajectory, set to ride a wave of success with a projected CAGR of 21.2% until 2031! 📈   LBPs are revolutionizing healthcare with their potential to harness the power of living organisms for therapeutic purposes. This growth is a testament to the dedication and innovation within the industry. We're witnessing the incredible impact of LBPs firsthand. From enhancing gut health to fighting disease, LBPs are changing the game in healthcare and paving the way for a healthier future. This comprehensive study provides us with valuable insights that drive our industry forward.  Let's keep pushing the boundaries of science and continue collaborating to unlock the full potential of Live Biotherapeutic Products! Read details here:  https://lnkd.in/ggx5mMca https://lnkd.in/g8RPpZyJ    #LBPGrowth #ListLabs #Innovation #HealthcareRevolution #Biotherapeutics #FutureOfHealthcare 

Would you like to know how the piCode technology can help optimize your experimental processes? Come visit Plexbio at Medica, and the answer will be revealed. #Liquidbiophy #PlexBio #PreciseMedicine

🚀 Exciting Times Ahead in IVD and Life Science! 🧬✨ Some groundbreaking tech trends I think will reshape the IVD and Life Science Industry landscape in 2024.    #IVD #LifeScience #GlobalSales #DigitalTransformation #HealthcareInnovation #SalesStrategy #GlobalReach #BiotechInnovation #MarketTrends

As we look toward a promising 2024, the ADVI Health team is reflecting on some of the biggest issues, milestones, and regulations that helped to shape the #healthcare landscape in 2023. We asked #ADVIExperts to share the first key phrase or keyword that comes to mind regarding our critical work with clients. Which of the following responses resonate most with you and your organization? ▫️Innovation, specific to the development of new targeted therapies [and ADVI's unique opportunity to work at the intersection of molecular diagnostics and precision therapeutics] ▫️Real-time insights and evidence generation ▫️Software, specific to #healthpolicy developments for prescription digital therapeutics and artificial intelligence ▫️Empirically derived insights Hear from Lauren Feldman, Caitlin Sheetz, Michael Beebe, Peter Kardel, and more: https://lnkd.in/gF6H5b5p

The numbers of sequences we're getting are so much greater than the old days of radioactive Sanger sequencing on a gel - is there a particular throughput that we need to arrive at wherever we're trying to get? Or are we trapped in the 'when all we have is a hammer, everything's a nail' paradigm? That is - sequencing data throughput rather than the point of generating the data exercise, has become the point? We have huge Institutions which deal in sequence data and analysis - are we pursuing this paradigm because we've the infrastructure to do it? What's the answer to this question? A little information on the effects of lifestyle factors on ageing and the omics compartments and a little information on gut biome diversity with a certain lifestyle - alongside perhaps a little proof on lifestyle and biological ageing reversal would be nice - but we kinda' know what the factors which increase / decrease biological ageing will be - from thinking about the problem alongside some of the data we already have. Still I suppose it's nice to prove - but after proof - we'll be able to settle into a more measured relationship with sequence generation? Certainly fully automatable - experimentally and analytically - trivial for AI.

Reasons to come by booth 630 and meet the Sannova Analytical team? 1.) We’ll be discussing the difference that pairing excellent science with a boutique project delivery approach can make for your studies. — Your program receives our complete attention, and we help our customers solve their most difficult problems in bioanalysis. 2.) We schedule projects in our lab one week after our customers give us the green light! — No waiting on team assignment, and we act as an integrated extension of your team. The complexities of developing #advancedtherapies are tough enough to navigate, don’t add an overly complex CRO to the mix, choose #SannovaAnalytical!

Dimensions will be at the World CB & CDx in Boston from September 5-8. Join us at booth E13 & don't miss our session by Lauren E. Black on Day 2! see: https://lnkd.in/dkmqfFJq or the details here👇 🕛 Session: Challenges in Biomarker Discovery: How to Avoid Missing Information About any New Biomarker Discussed in Literature and Patents 🗣️ Speaker: Lauren Black, Product Solutions Manager at Dimensions 📖 Synopsis: Perform complex and time-consuming scientific literature analysis in a real time Discover all proteins related to your specific disease setting Get comprehensive insights driven by the biggest protein ontology in the field (more than 6M concepts and synonyms) Get aware about new biomarkers discussed in patents but not literature yet, and vice versa Don't miss out on this opportunity to enhance your biomarker discovery efforts! 👩🔬🔬 #BiomarkerDiscovery #ScientificResearch #Innovation

I'm quite mystified by Johannas' comparison here between Illumina NovaSeq, NextSet, and Element Biosciences Aviti. I get his point that (at least at list prices) Aviti is a better deal than NextSeq for the mid-market. But he also compares Aviti against NovaSeq and concludes that because the per Gb consumable cost is about the same, and capex is much lower for Aviti, Aviti > Novaseq 🤔 But he seems to completely ignore throughput I don't see it in his spreadsheet😳 From a quick look at the specs of the NovaSeq X, throughput max is 16Tb/run; Aviti is max is 600Gb [corrected, sorry]. So if you need serious throughput (target market for an X) you would buy an X for about $1M. To match that with Aviti you would need 16000G/600G = 27 Avitis [corrected], which would cost about $8M or more 8 times the capex of an X. What am i missing here?! Am I misunderstanding him or doing my math wrong? 🤪